IM Cannabis Resultados de beneficios anteriores
Pasado controles de criterios 0/6
IM Cannabis's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 34.7% per year.
Información clave
-13.2%
Tasa de crecimiento de los beneficios
6.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 23.1% |
| Tasa de crecimiento de los ingresos | 34.7% |
| Rentabilidad financiera | -276.1% |
| Margen neto | -28.2% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Slammed 28% IM Cannabis Corp. (CSE:IMCC) Screens Well Here But There Might Be A Catch
Sep 13
A Piece Of The Puzzle Missing From IM Cannabis Corp.'s (CSE:IMCC) Share Price
Jul 30Potential Upside For IM Cannabis Corp. (CSE:IMCC) Not Without Risk
Jul 19Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?
Dec 24Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)
Feb 05
What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?
Jan 08Desglose de ingresos y gastos
Cómo gana y gasta dinero IM Cannabis. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 50 | -14 | 19 | 0 |
| 31 Mar 24 | 48 | -15 | 20 | 0 |
| 31 Dec 23 | 49 | -9 | 22 | 0 |
| 30 Sep 23 | 53 | -15 | 18 | 0 |
| 30 Jun 23 | 54 | -17 | 21 | 0 |
| 31 Mar 23 | 54 | -17 | 23 | 0 |
| 31 Dec 22 | 54 | -23 | 24 | 0 |
| 30 Sep 22 | 50 | -22 | 32 | 0 |
| 30 Jun 22 | 44 | -16 | 32 | 0 |
| 31 Mar 22 | 38 | -10 | 30 | 0 |
| 31 Dec 21 | 34 | 0 | 29 | 0 |
| 30 Sep 21 | 29 | -10 | 27 | 0 |
| 30 Jun 21 | 27 | -12 | 23 | 0 |
| 31 Mar 21 | 23 | -24 | 23 | 0 |
| 31 Dec 20 | 16 | -29 | 19 | 0 |
| 30 Sep 20 | 13 | -7 | 14 | 0 |
| 30 Jun 20 | 10 | -10 | 13 | 0 |
| 31 Mar 20 | 8 | -1 | 11 | 0 |
| 31 Dec 19 | 9 | -7 | 10 | 0 |
| 30 Sep 19 | 8 | -8 | 9 | 0 |
| 30 Jun 19 | 7 | -6 | 7 | 0 |
| 31 Mar 19 | 6 | -6 | 5 | 0 |
| 31 Dec 18 | 5 | 2 | 3 | 0 |
| 31 Dec 17 | 4 | 1 | 2 | 0 |
Ingresos de calidad: IMCC is currently unprofitable.
Margen de beneficios creciente: IMCC is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: IMCC is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Acelerando crecimiento: Unable to compare IMCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: IMCC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rentabilidad financiera
Alta ROE: IMCC has a negative Return on Equity (-276.08%), as it is currently unprofitable.